pre-IPO PHARMA
COMPANIES
VC
JOBS
NEWS
CONTACT
Close ×
COMPANIES
VC
JOBS
NEWS
CONTACT
sonoma-biotherapeutics PRESS RELEASE ARCHIVE
May 31, 2023
Page Not Found
May 31, 2023
Page Not Found
Apr 11, 2023
Sonoma Biotherapeutics Appoints Leaders in Cell Therapy and Immunology to Scientific Advisory Board
Mar 28, 2023
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
Nov 10, 2022
Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Cell Therapy for Rheumatoid Arthritis at American College of Rheumatology Convergence 2022
Sep 7, 2022
Sonoma Biotherapeutics Appoints Jessica Stitt as Chief Financial Officer
Aug 24, 2022
Sonoma Biotherapeutics Enters Long-Term Lease Agreement to Establish a Treg Cell Therapy RandD and Manufacturing Center
Aug 17, 2022
Sonoma Biotherapeutics Expands Board of Directors with Appointments of Katina Dorton, J.D., MBA, and John Davis, M.D., MPH
Jun 8, 2022
Sonoma Biotherapeutics Announces FDA Clearance of Investigational New Drug Application for SBT115301, an Effector T Cell-Modulating Biologic for Autoimmune Diseases
Nov 16, 2021
Sonoma Biotherapeutics Appoints Heidi Hagen, MBA as Chief Technical Officer
Sep 16, 2021
Sonoma Biotherapeutics Expands Leadership Team with the Appointment of Doug Sheehy, J.D., as Chief Legal Officer and Secretary
Aug 4, 2021
Sonoma Biotherapeutics Raises $265 Million in an Oversubscribed Series B Financing to Translate the Promise of Cell Therapy into Curative Medicines for Autoimmune and Other Inflammatory Diseases
Sep 30, 2020
Sonoma Biotherapeutics Expands Series A Financing to $70 Million and Appoints Key Executives to Advance Regulatory T-cell Therapies in Autoimmune and Degenerative Diseases
Feb 6, 2020
Sonoma Biotherapeutics launches with $40 million in Series A funding to advance regulatory T cell therapy in autoimmune and degenerative diseases
